Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Athenex, Inc.
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- QuaDPharma, LLC., Kinex Pharmaceuticals, Axis Therapeutics Limited
- Kuur Therapeutics, Inc.